Patents Assigned to Novartis Pharma GmbH
-
Patent number: 8343984Abstract: Polymorphic forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide free base and salts thereof are prepared by various processes.Type: GrantFiled: July 18, 2006Date of Patent: January 1, 2013Assignees: Novartis AG, Novartis Pharma GmbHInventors: Paul W Manley, Wen-Chung Shieh, Paul Allen Sutton, Piotr “Peter” H Karpinski, Raeann Wu, Stéphanie M. Monnier, Jörg Brozio
-
Patent number: 8198289Abstract: The invention relates to particular crystal forms of the methanesulfonic acid addition salt of 4-(4 -methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide, certain processes for their preparation, pharmaceutical compositions containing these crystal forms, and their use in diagnostic methods or, preferably, for the therapeutic treatment of warm-blooded animals, especially humans, and their use as an intermediate or for the preparation of pharmaceutical preparations for use in diagnostic methods or, preferably, for the therapeutic treatment of warm-blooded animals, especially humans.Type: GrantFiled: January 14, 2011Date of Patent: June 12, 2012Assignees: Novartis AG, Novartis Pharma GmbHInventor: Michael Mutz
-
Patent number: 8163904Abstract: Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide are prepared by various processes.Type: GrantFiled: July 18, 2006Date of Patent: April 24, 2012Assignees: Novartis AG, Novartis Pharma GmbHInventors: Paul W Manley, Wen-Chung Shieh, Paul Allen Sutton, Piotr H Karpinski, Raeann Wu, Stéphanie Monnier, Jörg Brozio
-
Patent number: 8105587Abstract: This invention relates to methods employing IL-1?-ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1? ligand-IL-1 receptor interaction, IL-1? antibodies or IL-1 receptor antibodies, e.g. IL-1? binding molecules as described herein, e.g. antibodies disclosed herein, e.g. IL-1? binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1? ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.Type: GrantFiled: October 24, 2006Date of Patent: January 31, 2012Assignees: Novartis AG, Novartis Pharma GmbHInventors: Phil Lowe, Hermann Gram, Thomas Jung, Timothy Wright, Trevor Mundel
-
Patent number: 8012477Abstract: An IL-17 binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of a solid or hematological malignant diseases.Type: GrantFiled: January 30, 2007Date of Patent: September 6, 2011Assignees: Novartis AG, Novartis Pharma GmbHInventors: Michael Cooreman, Franco E. Di Padova
-
Patent number: 7998687Abstract: The invention relates to the analysis and identification of genes that are modulated in transplant rejection. This alteration of gene expression provides a molecular signature to accurately detect transplant rejection.Type: GrantFiled: April 19, 2007Date of Patent: August 16, 2011Assignees: Novartis AG, Novartis Pharma GmbHInventor: Peter Grass
-
Patent number: 7893076Abstract: The invention relates to the F-crystal form, G-crystal form, H-crystal form, I-crystal form and K-crystal form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide, certain processes for their preparation, pharmaceutical compositions containing these crystal forms, their use in diagnostic methods or for the therapeutic treatment of warm-blooded animals, and their use as an intermediate or for the preparation of pharmaceutical preparations for use in diagnostic methods or for the therapeutic treatment of warm-blooded animals, especially humans.Type: GrantFiled: November 23, 2006Date of Patent: February 22, 2011Assignees: Novartis AG, Novartis Pharma GmbHInventor: Michael Mutz
-
Publication number: 20100303865Abstract: The present invention relates to the use of compounds of formula (I), wherein R1, X, Y, Z and m are as defined in the description, in the free form or in salt form either alone or in combination with a vaccine component, for controlling fish parasites, in particular sea lice.Type: ApplicationFiled: August 28, 2006Publication date: December 2, 2010Applicants: NOVARTIS AG, NOVARTIS PHARMA GMBHInventors: Jacques Bouvier, John Marshall, Richard Hunter
-
Publication number: 20090318445Abstract: The invention relates to novel compounds that are inhibitors of peptidyl deformylase (PDF). The compounds are useful as antimicrobials and antibiotics. The compounds of the invention display selective inhibition of peptidyl deformylase versus other metalloproteinases such as MMPs. Methods of preparation and uses of the compounds are also disclosed.Type: ApplicationFiled: December 28, 2006Publication date: December 24, 2009Applicants: NORVARTIS AG, NOVARTIS PHARMA GMBHInventors: Arkadius Pichota, Jeyaraj Duraiswamy, Zheng Yin, Thomas Hugo Keller, Mark Schreiber
-
Publication number: 20090306138Abstract: Compounds of formula I in free or salt form, wherein T, X, Y, U, R1, R2, m, n and p have the meanings as indicated in the specification, are useful for treating conditions mediated by CCR3. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.Type: ApplicationFiled: January 28, 2005Publication date: December 10, 2009Applicant: NOVARTIS PHARMA GMBHInventors: Gurdip Bhalay, Andrew Dunstan, Angela Glen, Trevor John Howe, Clive McCarthy
-
Publication number: 20090197902Abstract: The invention relates to the use of compounds of the general formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, X1 and X2 have the significances given in claim 1, and optionally the enantiomers and geometrical isomers thereof, for controlling parasites on warm-blooded animals.Type: ApplicationFiled: February 27, 2009Publication date: August 6, 2009Applicants: Novartis AG, Novartis Pharma GmBHInventors: Jorg Fruchtel, Noelle Gauvry, Sandra Schorderet-Weber, Tania Cavaliero, Jacques Bouvier, Francois Pautrat
-
Publication number: 20080139551Abstract: treatment of a variety of disorders, including the treatment of pathological conditions associated with tumor necrosis factor alpha. The inhibitors of tumor necrosis factor alpha have the following structures: including stereoisomers, pharmaceutically acceptable salts, and solvates thereof, wherein substituents are as defined herein. Compositions containing an inhibitor of tumor necrosis factor alpha in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.Type: ApplicationFiled: August 21, 2007Publication date: June 12, 2008Applicants: AVANIR PHARMACEUTICALS, NOVARTIS PHARMA GMBHInventors: Jagadish Sircar, Sunil Kumar, Timothy James Davis, Wenbin Ying, Peter Nussbaumer, Andreas Billich
-
Patent number: 6740672Abstract: 5HT3-receptor-antagonists for the treatment of CFS (Chronic Fatigue Syndrome) are disclosed.Type: GrantFiled: September 4, 2001Date of Patent: May 25, 2004Assignee: Novartis Pharma GmbHInventor: Dieter Welzel